Continuous Glucose Monitoring (CGM) systems have been commercially
available for several years and have been of benefit in patients with Diabetes.
However, many commercially available sensors provide added burden to the
lives of people with diabetes, requiring multiple calibrations, separate
transmitters and sensors, and may be limited to a sensor-life of only 7 days.
While there have been recent advances in CGM technology, further improvements relating to sensor accuracy, reliability, reduced number of blood glucose calibrations, and comfort during sensor insertion and wear are required.
The Medtronic Extended Life Glucose Sensor is a single-use integrated disposable device, integrating the sensor and transmitter, requiring no calibrations and with a sensor-life of up to 17 days.
The Diabetes Technology Research Group based out of St Vincent’s Hospital Melbourne are seeking to collect performance data on the Medtronic Extended Life Sensor.
This study is recruiting people with Type 1 Diabetes for a study duration of approximately 18 days, including 6 in-patient visits to St Vincent’s Hospital Melbourne during that time, including four day-long meal tests each lasting 6-7 hours on site.